April 25, 2018 / 12:48 PM / 5 months ago

BRIEF-Theravance Biopharma Says FDA Has Approved An Expanded Indication For Trelegy Ellipta

April 25 (Reuters) - Theravance Biopharma Inc:

* THERAVANCE BIOPHARMA HIGHLIGHTS APPROVAL OF EXPANDED INDICATION IN THE US FOR ONCE-DAILY TRELEGY ELLIPTA FOR TREATMENT OF COPD PATIENTS

* THERAVANCE BIOPHARMA INC - U.S. FDA HAS APPROVED AN EXPANDED INDICATION FOR TRELEGY ELLIPTA

* THERAVANCE BIOPHARMA INC - EXPANDED APPROVAL IN U.S. ALLOWS TRELEGY ELLIPTA TO BE USED AS A TREATMENT FOR A BROADER POPULATION OF COPD PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below